Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTerpath-014 adjuvant intismeran autogene with or without subcutaneous pembrolizumab versus placebo in high-risk stage I NSCLC after complete resection
MOH_2026-06-03_016861Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of intismeran autogene and pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoint: Disease-free survival. Planned start May 2026; status: not yet recruiting.
02
Drugs
intismeran autogenepembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2026-06-03_016861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-06-03_016861.